Evidence map›Paper›PMID 32991749›Full record

ArticleJournal of leukocyte biology2021

Reversal of sepsis-induced T cell dysfunction: OX-40 to the rescue?

Edward R Sherwood, David L Williams

Open access · greenAbstract readEditorialComment
In one paragraph

Article in Journal of leukocyte biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Observational
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Edward R SherwoodDepartment of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
David L WilliamsCenter of Excellence in Inflammation, Infectious Disease and Immunity, East Tennessee State University, Johnson City, Tennessee, USA.
East Tennessee State University · USVanderbilt University Medical Center · US

Funding

Training Innate Immunity: A new approach to the treatment of SepsisR01GM119197 · NIGMS · EAST TENNESSEE STATE UNIVERSITY · PI SHERWOOD, EDWARD R, WILLIAMS, DAVID L. · 2016 to 2024
$4.6M
Innate Immunity and Cardiovascular Function in SepsisR01GM083016 · NIGMS · EAST TENNESSEE STATE UNIVERSITY · PI LI, CHUANFU, WILLIAMS, DAVID L. · 2009 to 2021
$3.8M
Macrophage mitochodrial reprogramming and innate immune memoryR01AI151210 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SHERWOOD, EDWARD R · 2020 to 2024
$2.1M
NIAID NIH HHS R01 AI151210NIGMS NIH HHS R01 GM083016NIGMS NIH HHS R01 GM119197NIH HHS AI151210NIH HHS C06RR0306551NIH HHS GM083016NIH HHS GM119197
6 · The paper itself

Abstract

The study of Unsinger and colleagues provide important insights into OX40 mediated immunotherapy as a potential approach for the treatment of sepsis induced immune suppression.

Indexed as

Receptors, OX40SepsisAntibodiesHumansImmunotherapyT-LymphocytesAntibodiesReceptors, OX40

Identifiers

PMID32991749
PMCPMC7987777
OpenAlexW3089778105

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.